杜拉古胺 (Trulicity) 诱导的急性胰腺炎:一个病例报告
Abu Baker Khan1, Aimal Shah2,3, Saad Ahmad4
1Internal Medicine, Ayub Teaching Hospital, Abbottabad, PAK.
Cureus
|June 7, 2023
概括
这份病例报告详细介绍了一名患者,在杜拉格卢提德 (Trulicity) 剂量增加后,他出现了急性胰腺炎. 它强调了这种2型糖尿病药物的潜在不良影响.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 的管理通常涉及葡萄糖类-1 (GLP-1) 受体激活剂.
- 杜拉格卢提德是一种长效GLP-1模拟剂,增强胰岛素分泌并降低食欲.
- 标准的杜拉格卢提德剂量为每周0.75毫克,可用于血糖控制.
研究的目的:
- 报告一例急性胰腺炎的病例,该病例发生在接受杜拉格卢提德治疗的患者中.
- 讨论杜拉格卢提德对胰腺健康的潜在不良影响.
- 为了强调在使用杜拉格卢提德的患者中监测胰腺酶水平的重要性.
主要方法:
- 一个37岁的男性患有2型糖尿病的病例报告.
- 患者出现了急性胰腺炎的症状,最近增加了杜拉格卢提德的剂量.
- 诊断评估包括升高的脂酶水平和腹部CT扫描确认胰腺炎.
主要成果:
- 患者在从每周0.75毫克升至1.5毫克的杜拉格卢提德剂量升级后发生了急性胰腺炎.
- 升高的脂酶水平 (1508) 和胰腺脂肪链的CT发现与急性胰腺炎一致.
- 虽然杜拉格卢提德可以引起轻微的胰腺酶升高,但很少报告严重的胰腺炎.
结论:
- 这一案例表明,杜拉格卢提德的使用,特别是剂量增加后,与急性胰腺炎之间可能存在关联.
- 医疗保健提供者应对服用杜拉格卢提德的患者胰腺炎症状保持警.
- 在接受杜拉格卢提德治疗的患者中,监测胰腺酶水平可能是合理的.
相关概念视频
Acute Pancreatitis II: Clinical Manifestations and Management
155
Acute pancreatitis presents a complex medical emergency characterized by rapid onset inflammation of the pancreas, demanding timely diagnosis and management to prevent complications. The condition primarily manifests through severe upper abdominal pain that often radiates to the back. This pain intensifies following the consumption of fatty foods. Accompanying symptoms such as nausea, vomiting, abdominal distention, fever, dyspnea, cyanosis, and jaundice can vary in intensity but significantly...
155
Glucagon-like Receptor Agonists
370
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
370
Acute Pancreatitis I: Introduction
418
Pancreatitis is inflammation of the pancreas, an organ located behind the stomach. It can be either acute or chronic.
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
Acute pancreatitis is characterized by rapid inflammation of the pancreas, often caused by factors like gallstone blockage or excessive alcohol consumption. Chronic pancreatitis, on the other hand, is a slow, progressive inflammation that may result from long-term alcohol abuse, obstructions in the pancreatic duct, or genetic factors.
The causes of acute pancreatitis include:
418
Chronic Pancreatitis I: Introduction
116
The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
116
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Chronic Pancreatitis II: Collaborative Care
116
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
116


